VIV:TSX.V; VIVXF:OTCQB

Avivagen Inc.

Avivagen is developing and commercializing products that promote health in animals and humans. The Corporation’s unique OxC-beta™ technology is a proprietary, first-in-class source of β-carotene-oxygen copolymer compounds that confer a variety of non-vitamin A health benefits. These benefits have wide, global utility, including replacement of antibiotics in livestock feeds, as well as for food-production conditions where antibiotics cannot be used, and supporting good health in companion animals.

VIV:TSX.V VIVXF:OTCQB

View Company News

Visit Company Website

Expert Comments:

Global Distribution Deal for Antibiotic Alternative for Livestock ‘Could Be a Game Changer’
(10/25/21)

Analyst David Bautz at Zacks Small-Cap Research wrote bullishly on Avivagen's eight-year distribution deal targeting the U.S., Brazil, and Thailand in an Oct. 11 report: The AB Vista deal “could be a game changer for the company as Avivagen now has a global partner that gives immediate credibility to the OxC-beta technology."

Joseph Gomes, Noble Capital Markets

(10/19/21)

"Avivagen Inc. signed a significant new purchase agreement to supply its largest customer in Asia with a 6.3 ton order of OxC-beta Livestock. The shipment represents a 43% increase in size over the customer's previous order and continues a trend of increased reorder size among this and other OxC-beta customers worldwide."

Joseph Gomes, Noble Capital Markets

(10/7/21)

"Avivagen Inc. has entered into a distribution agreement focused on the U.S., Brazil and Thailand markets; the eight-year agreement is with AB Vista. We expect the agreement to expand the adoption and use of OxC-beta in a number of high-value feed production markets worldwide; the AB Vista agreement should bring additional credibility for OxC-beta across the feed additive industry."

Joseph Gomes, Noble Capital Markets

(9/30/21)

"Avivagen Inc.'s pipeline continues to expand. . .during Q3/21 the company secured a new customer win in Western Mexico, recorded its first order from Brazil and secured the first order with a major swine and poultry producer in Thailand. Avivagen continues to move forward for regulatory approval in the key markets of China and Vietnam."

David Bautz, Zacks Small-Cap Research

(6/14/21)

"Subsequent to the end of the quarter the company secured a new customer in Western Mexico, initiated discussions with potential partners to ramp up sales efforts in the U.S. following termination of its previous exclusive distribution agreement, recorded the first order from Brazil, and secured the first order with a major swine and poultry producer in Thailand. . .We are very encouraged how Avivagen continues to expand its customer base and increase the size and frequency of orders for OxC-beta Livestock and we expect revenues to begin to ramp up in the second half of fiscal year 2021."

Joseph Gomes, Noble Capital Markets

(6/4/21)

"Momentum continues to build for Avivagen Inc.; just since Q2/21E, the company secured a new customer in western Mexico, recorded its first order from Brazil and secured its first order with a major swine and poultry producer in Thailand. We expect these new customers, ongoing trials and existing customers to drive revenue higher going forward."

Joseph Gomes, Noble Capital Markets

(5/4/21)

"Avivagen Inc. announced it entered into a contract for a four tonnes per month recurring order from Meyenberg International, the company's consultant in Mexico. . .The Meyenberg order continues the order momentum for Avivagen, building off the April 26th announcement that Avivagen received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta Livestock, the largest single shipment purchase order of OxC-beta to date. . .. We believe the company is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."

More Expert Comments

Joseph Gomes, Noble Capital Markets (4/26/21) "Avivagen Inc. announced it has received a purchase order for a single shipment of 4.4 mt of OxC-beta Livestock; this represents the largest single shipment purchase order of OxC-beta to date and represents a 10% increase in size over the previous record single shipment order. This one order represents more than 40% of the previous year's total volume."

David Bautz, Zacks Small-Cap Research (3/8/21) "Avivagen Inc. delivered a total of approximately 5 t of OxC-beta Livestock last year, thus the orders received thus far for 2021 already exceed last year's totals. . .the company has announced that two publications describing trials performed with OxC-beta will be published in leading, peer-reviewed scientific journals." —Zacks Small-Cap Research

Joseph Gomes, Noble Capital Markets (3/5/21) "Another manuscript reporting the benefits of Avivagen Inc.'s OxC-beta Livestock, this time for broiler poultry, has been approved for publication by Poultry Science, a leading peer-reviewed journal; in the two trials reported on, OxC-beta groups achieved significantly improved growth performance measures over the control groups. These peer-reviewed publications not only validate existing customers but provide confidence to new customers to adopt OxC-beta."

Joseph Gomes, Noble Capital Markets (3/1/21) "We are initiating research coverage on Avivagen Inc. with an Outperform rating. . .we believe the company is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition."

David Bautz, Zacks Small-Cap Research (12/23/20) "Avivagen Inc. achieved a number of important milestones in 2020, including approval of OxC-beta in Brazil and Malaysia, a record 4 ton order from UNAHCO, the company's distribution partner in the Philippines, and a 10 ton order from Industrias Melder in Mexico. FY20 revenues were CA$1.2M, and for FY21 we are currently forecasting sales of CA$3M based on increased order sizes from current customers and expansion of the customer base." —Zacks Small-Cap Research

David Bautz, Zacks Small-Cap Research (9/8/20) "Avivagen Inc. announced financial results for Q3 FY20 that ended July 31, 2020; the company reported revenues of CA$612,530, an increase of CA$600,046 compared to Q3 FY19, which was driven by two major sales of OxC-beta during the quarter and the largest ever orders from Mexico-based Industrias Melder and Philippines-based UNAHCO. In addition, during the quarter, regulatory approval was secured in Brazil." —Zacks Small-Cap Research

SmallCapsDaily (7/23/20) "Enhancing livestock health without the use of antibiotics has become a must in order to prevent the emergence of deadly diseases including so called superbugs. Avivagen Inc. is a Life Sciences player that caters directly to this need and is at a very interesting juncture today. The company is building a compelling growth story as it has gone on to receive numerous country approvals across many large livestock markets in the world."

David Bautz, Zacks Small-Cap Research (6/9/20) "Avivagen Inc. recently announced an upsized order of OxC-beta Livestock from Mexico-based Industrias Melder following positive results from two dairy animal tests conducted by one of Industrias Melder's key customers. This initial sale could lead to a formal long-term relationship and help Avivagen enter the Mexican market, which has annual feed sales of 36 Mt." —Zacks Small-Cap Research

David Bautz, Zacks Small-Cap Research (3/11/20) "Avivagen Inc. announced positive and statistically significant results from its New Zealand dairy trial showing that OxC-beta has an effect against subclinical mastitis. There was a 13.9% rate of resolution of bacterial infection in cows fed feed containing OxC-beta compared to a 6.9% resolution rate in the group fed the control feed containing no antibiotics." — -Zacks Small-Cap Research

Clive Maund, CliveMaund.com (1/31/20) "Given the huge strides that Avivagen Inc. is making towards its objectives, it is truly astounding that its stock hasn't taken off higher already, especially given that it still has a relatively modest number of shares in issue. . .it looks like it could very soon. . .the company looks like a most attractive stock here, so we stay long and it is rated an immediate Strong Buy."

David Bautz, Zacks Small-Cap Research (1/10/20) "Avivagen Inc. entered into an agreement with COFCO Biotechnology Co. Ltd. in which COFCO will assist the company in securing regulatory approval for OxC-beta Livestock in China. . .we believe it is a great partner to assist Avivagen. . .China represents a tremendous opportunity for it as the Chinese government has announced a plan to ban all antibiotics in livestock feed by July 2020." — -Zacks Small-Cap Research

Experts Following This Company

David Bautz, Senior Biotechnology Analyst – Zacks Small-Cap Research
Joseph Gomes, Senior Research Analyst – Noble Capital Markets

The information provided above is from analysts, newsletters, the company and other contributors.

Avivagen Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights

	In February, completed a $7.5MM financing, which was 50% over subscribed at an increased amount.
	Announced two significant sales contracts, one for 10 tonnes of OxC-beta Livestock to Melder and 6 tonnes to Transformadora, both in Mexico
	Published papers in two respected peer review journals, essential for scientific validation of our product

catalyst Calendar